You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Immunohistochemical Expression of Stem Cell, Endothelial Cell, and Chemosensitivity Markers in Primary Glioma Spheroids Cultured in SerumContaining and SerumFree Medium

Christensen, Karina PhD; Aaberg-Jessen, Charlotte MS; Andersen, Claus DMSc; Goplen, Dorota MD, PhD; Bjerkvig, Rolf Professor; Kristensen, Bjarne Winther MD, PhD

Neurosurgery:
doi: 10.1227/01.NEU.0000368393.45935.46
Experimental Studies
Abstract

OBJECTIVE: To investigate the influence of serum-free medium (SFM) supplemented with epidermal growth factor and basic fibroblast growth factor compared with conventional serum-containing medium (SCM) on the phenotype of organotypic primary spheroids from seven gliomas.

METHODS: Paraffin sections of the original surgical specimens, primary glioma spheroids, and U87 derived spheroids were stained immunohistochemically with the stem cell markers CD133, podoplanin, Sox2, Bmi-1, and nestin; the endothelial cell markers CD31, CD34, and Von Willebrand Factor (VWF); the chemosensitivity markers P-glycoprotein and tissue inhibitor of metalloproteinases-1 (TIMP-1); and glial fibrillary acidic protein, neural cell adhesion molecule CD56, and the proliferation marker Ki67.

RESULTS: Scoring of the immunohistochemical stainings showed that the expression of CD133 and all other markers included was preserved in primary spheroids, confirming the in vivo-like nature of these spheroids. Spheroids in SFM better mimicked the in vivo phenotype with significantly more CD133, CD34, VWF, P-glycoprotein, TIMP-1, and Ki67 compared with SCM.

CONCLUSION: In this first study of the influence of SFM on primary glioma spheroids, the conditions favored an in vivo-like phenotype with increased expression of CD133. More vascular structures were found in SFM, suggesting that the close relationship between blood vessels and tumor stem-like cells was better preserved in this medium.

Author Information

Department of Pathology, Odense University Hospital, Odense, Denmark (Christensen) (Aaberg-Jessen) (Kristensen)

Department of Neurosurgery, Odense University Hospital, Odense, Denmark (Andersen)

Department of Biomedicine, University of Bergen, Bergen, Norway (Goplen) (Bjerkvig)

NorLux Neuro-Oncology, Centre de Recherche Public Santé, Luxembourg, Luxembourg (Bjerkvig)

Reprint requests: Bjarne Winther Kristensen, MD, PhD, Department of Pathology, Odense University Hospital, Winsløwparken 15, 5000 Odense C, Denmark. E-mail: bjarne.winther.kristensen@ouh.regionsyddanmark.dk

Received, July 20, 2009.

Accepted, December 27, 2009.

Copyright © by the Congress of Neurological Surgeons